Table 1.
Sample demographic and clinical characteristics
| Variable | M (SD), Median (IQR) or % (n) n = 187 |
|---|---|
|
| |
| Gender: Female | 99% (186) |
| Age | 57.7 (12.5) |
| Race: | |
| White | 87% (161) |
| Black/African American | 7% (13) |
| Asian | 4% (8) |
| Other | 2% (4) |
| Ethnicity: Hispanic/Latino | 4% (7) |
| Body Mass Index (BMI) | 26.11 (5.69) |
| Household Income | |
| ≥ $100,000 | 65% (93) |
| $75,000–$99,999 | 14% (20) |
| $50,000–$74,999 | 14% (20) |
| $0–$49,999 | 8% (11) |
| Full-time employment | 54% (100) |
| Education (n = 186) | |
| College Graduate or more | 85% (159) |
| Partial College | 12% (22) |
| High School Diploma or Less | 3% (5) |
| Marital status | |
| Married or living with partner | 51% (95) |
| Single | 30% (57) |
| Divorced, separated, or widowed | 19% (35) |
| Time since diagnosis (months) | 35 (21–63) |
| Cancer stage | |
| IA | 54% (100) |
| IB | 0.5% (1) |
| IIA | 25% (47) |
| IIB | 10.5% (19) |
| IIIA | 7% (13) |
| IIIC | 3% (6) |
| Cancer treatment types (n = 184) | |
| Current hormone therapy | 66% (121) |
| Received chemotherapy | 60% (110) |
| Family history of breast/ovarian cancer | 41% (76) |
| Medical comorbidities | |
| High cholesterol | 21% (39) |
| High blood pressure | 20% (38) |
| Arthritis | 16% (30) |
| Thyroid diseases | 8% (15) |
| Musculoskeletal disorders | 5.9% (11) |
| Lung diseases | 5.4% (10) |
| Heart disease | 3.2% (6) |
| Other | 3.2% (6) |
| Medication regimen (n = 186) | |
| Hormone therapy (1 or more) | 94% (174) |
| Tamoxifen | 44% (81) |
| Letrozole | 36% (67) |
| Cancer therapy (1 or more) | 51% (95) |
| Paclitaxel | 37% (68) |
| Cyclophosphamide | 35% (66) |
| Psychiatric medication (1 or more) | 60% (110) |
| Diazepam | 33% (62) |
| Lorazepam | 28% (52) |
| Behavioral assessments | |
| FCRI: Fear of Cancer Recurrence Inventory (n = 170) | 18.6 (7.3) |
| PCL-5: PTSD Checklist-5 (n = 173) | 8 (3–19) |
| PHQ-8: Patient Health Questionnaire Depression (n = 176) | 3 (1–7) |
| ASI: Anxiety Sensitivity Index (n = 173) | 17 (8–27) |
| PSS: Perceived Stress Scale (n = 176) | 14 (7.1) |
| FACT-G: Functional Assessment of Cancer Therapy (n = 159) | 82 (71–93) |
| MPQ: McGill Pain Questionnaire 2 (n = 174) | 8 (6–12) |
| FSI: Fatigue Symptom Inventory (n = 170) | 29.5 (11–55) |